Perth Children's Hospital

Running trials

• Not yet recruiting

  IBIS - Investigating Reliability of BIS and SEDLINE Monitoring in Children With Developmental and Epileptic Encephalopathies (DEE).

  NCT07585643· Telethon Kids Institute· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Pfizer· Source

• Recruiting

  A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  NCT07306832· Phase 1· AbbVie· Source

• Recruiting

  Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery

  NCT07351149· Uppsala University· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  NCT06333899· Early phase 1· Nationwide Children's Hospital· Source

• Recruiting

  ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  NCT06838676· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  Study of Olutasidenib and Temozolomide in HGG

  NCT06161974· Phase 2· Rigel Pharmaceuticals· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Recruiting

  Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  NCT05843253· Phase 2· Nationwide Children's Hospital· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Recruiting

  Targeted Pediatric High-Grade Glioma Therapy

  NCT05839379· Nationwide Children's Hospital· Source

• Recruiting

  Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

  NCT06208657· Phase 1/2· Australian & New Zealand Children's Haematology/Oncology Group· Source

• Recruiting

  A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

  NCT05991388· Phase 2/3· University of Birmingham· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia

  NCT06166706· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Active, not recruiting

  Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

  NCT05782907· Phase 3· AbbVie· Source

• Active, not recruiting

  Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

  NCT05830084· Phase 1· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  NCT05286788· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  NCT05233397· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  Precision Medicine for Every Child With Cancer

  NCT05504772· Australian & New Zealand Children's Haematology/Oncology Group· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source

• Active, not recruiting

  Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

  NCT05206357· Phase 1· Genmab· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· PedAL BCU, LLC· Source

• Active, not recruiting

  Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  NCT04759586· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  NCT04994132· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04320888· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  NCT04775485· Phase 2· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  NCT04655404· Early phase 1· Nationwide Children's Hospital· Source

• Active, not recruiting

  Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

  NCT04385277· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

  NCT04195399· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

  NCT04323046· Phase 1· Sabine Mueller, MD, PhD· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· University of Birmingham· Source

• Recruiting

  A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  NCT04293562· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

  NCT04195555· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

  NCT04106219· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  NCT03817398· Phase 2· Children's Oncology Group· Source

• Recruiting

  Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  NCT03959085· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

  NCT03773965· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582· Phase 3· Children's Oncology Group· Source

Showing 50 of 67.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers27 recruiting
• Acute lymphoblastic leukaemia6 recruiting
• Glioblastoma4 recruiting
• Sarcoma3 recruiting
• Acute myeloid leukaemia2 recruiting
• Kidney cancer2 recruiting
• Type 1 diabetes2 recruiting
• Chronic kidney disease1 recruiting
• Down syndrome1 recruiting
• Epilepsy1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Psoriatic arthritis1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

  NCT06439277· Phase 3· Eli Lilly and Company· Source

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Respirion Pharmaceuticals Pty Ltd· Source

• Completed

  A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

  NCT05260021· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

  NCT04238819· Phase 1/2· Eli Lilly and Company· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Completed

  COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

  NCT03206021· Phase 1· The Hospital for Sick Children· Source

• Completed

  Re-Irradiation of Progressive or Recurrent DIPG

  NCT03126266· University of Calgary· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507· Phase 2· Children's Oncology Group· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Children's Oncology Group· Source

• Completed

  Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745· Children's Oncology Group· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Children's Oncology Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Type 1 diabetes30 works · 2 trials